I N V E S T O R S   &   M E D I A

Skinap Therapeutics is a clinical biopharmaceutical company committed to developing medicines and medical devices for life-threatening and non-healing wounds and tissue failure diseases.

Skinap has a portfolio of novel product candidates targeting large-area and severe wounds, SAST2. Skinap’s lead program, supermembrane (Skinap-278), is in approaching phase I clinical development for life-threatening wounds.

Skinap is developing its next generation of modulators, including Skinap-176 and Skinap-352, in various wounds and tissue failure diseases.​

Investor inquiries: info@skinapus.com

Media inquiries: media@skinapus.com

Skinap Therapeutics Inc.​​

Address: 675 West Kendall Street
                Cambridge, MA  02142

Email Us For More Information: info@skinapus.com